Showing 2611-2620 of 6036 results for "".
- BostonSight Receives MMAP Grant to Expand and Automate Scleral Lens Manufacturinghttps://modernod.com/news/bostonsight-receives-mmap-grant-to-expand-and-automate-scleral-lens-manufacturing/2481848/BostonSight, a nonprofit healthcare organization that advances the treatment of diseased and damaged corneas and dry eye, announced it has received a $200,000 manufacturing grant from the Massachusetts Manufacturing Accelerate Program (MMAP) to advance its scleral lens manufacturing capabili
- Otsuka and ShapeTX Collaborate to Develop AAV Gene Therapies for Ocular Diseaseshttps://modernod.com/news/otsuka-and-shapetx-collaborate-to-develop-aav-gene-therapies-for-ocular-diseases/2481832/Otsuka Pharmaceutical and ShapeTX, a programmable medicine company using artificial intelligence (AI) and RNA to combat genetic diseases, announced a multitarget collaboration to develop intravitreally delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional t
- Link Biologics and Théa Open Innovation Enter Partnership to Develop Drug Candidate for Dry Eye Diseasehttps://modernod.com/news/link-biologics-and-thea-open-innovation-enter-partnership-to-develop-drug-candidate-for-dry-eye-disease/2481828/Link Biologics Limited and Théa Open Innovation announced that they have entered into an agreement to co-develop Link_TSG6 for the treatment of dry eye disease (DED) and other ophthalmology indications, worldwide excluding Asia. Link_TSG6 is a biological drug based on human TSG-6
- Business Executive Alex Gorsky Joins Neurotech’s Board as Lead Directorhttps://modernod.com/news/business-executive-alex-gorsky-joins-neurotechs-board-as-lead-director/2481827/Neurotech Pharmaceuticals announced that Alex Gorsky has been elected to Neurotech’s board as Lead Director. Mr. Gorsky is the former Chairman and CEO of Johnson & Johnson. Under Mr. Gorsky’s leadership, Johnson & Johnson grew to become one of world’s larg
- Novartis to Discontinue Development of GA Gene Therapyhttps://modernod.com/news/novartis-to-discontinue-development-of-ga-gene-therapy/2481824/Following weak phase 2 clinical data, Novartis decided to discontinue the clinical development of its geographic atrophy gene therapy candidate GT005, which it acquired as part of its acquisition of Gyroscope Therapeutics. The announcement was made by investment film Syncona, which prev
- Alcon: Cataract Surgery with AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependencehttps://modernod.com/news/alcon-cataract-surgery-with-acrysof-iq-vivity-iols-demonstrates-sustained-high-patient-satisfaction-and-reduced-spectacle-dependence/2481819/Alcon revealed final data from its Vivity Registry Study, which monitored real-world patient experiences for up to 12 months post-cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL). Data from
- Award-Winning Actress, Dancer and Director Debbie Allen Joins Prevent Blindness and Regeneron to Raise Awareness of Serious Retinal Diseaseshttps://modernod.com/news/award-winning-actress-dancer-and-director-debbie-allen-joins-prevent-blindness-and-regeneron-to-raise-awareness-of-serious-retinal-diseases/2481818/Award-winning actress, dancer and director Debbie Allen is partnering with Prevent Blindness and Regeneron to launch the 'Gr8 Eye Movement,' a new disease awareness campaign that aims to address gaps in how people understand the risk of developing certain serious retinal di
- Myra Vision Announces First-in-Human Use of its Calibreye Glaucoma Drainage Devicehttps://modernod.com/news/myra-vision-announces-first-in-human-use-of-its-calibreye-glaucoma-drainage-device/2481816/Myra Vision announced it has initiated its first-in-human clinical study of the Calibreye System, a glaucoma drainage device with titratable outflow control designed to achieve optimal reduction of IOP for moderate to severe glaucoma patients. The prospective, non-randomized open-label
- SightGlass Vision Reports 4-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenseshttps://modernod.com/news/sightglass-vision-reports-4-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/2481810/SightGlass Vision reported positive 4-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering el
- UC Irvine Researchers Discover a Nanobody that May Lead to Treatment for Retinitis Pigmentosahttps://modernod.com/news/uc-irvine-researchers-discover-a-nanobody-which-may-lead-to-treatment-for-retinitis-pigmentosa/2481805/A team of scientists from the University of California, Irvine, believe they have discovered a special antibody which may lead to a treatment for retinitis pigmentosa. The study,